Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AT-406 in combination with daunorubicin and cytarabine in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AT-406
• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Acute Myelogenous Leukemia (AML) | Phase 1 | Status: TERMINATED